+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gastric Cancer Drugs Global Market Report 2020

  • ID: 4871555
  • Report
  • December 2019
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott
  • AstraZeneca
  • Boston Biomedical
  • Danaher corporation
  • GlaxoSmithKline PLC
  • Merck KGaA
  • MORE

Gastric Cancer Drugs Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global gastric cancer drugs market.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:
Where is the largest and fastest growing market for the gastric cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Gastric Cancer Drugs Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market:

  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.

Scope

  • Markets Covered: 1) By Type: Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab 2) By End User: Hospitals, Clinics, Others 3) By Route of Administration: Oral, Parenteral
  • Companies Mentioned: Eli Lilly and company, Novartis, Merck KGaA, Otsuka Pharmaceutical, F. Hoffmann-La Roche
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • AstraZeneca
  • Boston Biomedical
  • Danaher corporation
  • GlaxoSmithKline PLC
  • Merck KGaA
  • MORE

1. Executive Summary

2. Gastric Cancer Drugs Market Characteristics

3. Gastric Cancer Drugs Market Size And Growth
3.1. Global Gastric Cancer Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Gastric Cancer Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Gastric Cancer Drugs Market Segmentation
4.1. Global Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

  • Doxorubicin Hydrochloride
  • Sunitinib
  • Docetaxel
  • Mitomycin
  • Fluorouracil
  • Imatinib
  • Trastuzumab

4.2. Global Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

  • Hospitals
  • Clinics
  • Others

4.3. Global Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

  • Oral
  • Parenteral

5. Gastric Cancer Drugs Market Regional And Country Analysis
5.1. Global Gastric Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Gastric Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Gastric Cancer Drugs Market
6.1. Asia-Pacific Gastric Cancer Drugs Market Overview
6.2. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Gastric Cancer Drugs Market
7.1. China Gastric Cancer Drugs Market Overview
7.2. China Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Gastric Cancer Drugs Market
8.1. India Gastric Cancer Drugs Market Overview
8.2. India Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Gastric Cancer Drugs Market
9.1. Japan Gastric Cancer Drugs Market Overview
9.2. Japan Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Gastric Cancer Drugs Market
10.1. Australia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Gastric Cancer Drugs Market
11.1. Indonesia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Gastric Cancer Drugs Market
12.1. South Korea Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Gastric Cancer Drugs Market
13.1. Western Europe Gastric Cancer Drugs Market Overview
13.2. Western Europe Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Gastric Cancer Drugs Market
14.1. UK Gastric Cancer Drugs Market Overview
14.2. UK Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Gastric Cancer Drugs Market
15.1. Germany Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Gastric Cancer Drugs Market
16.4. France Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.5. France Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Gastric Cancer Drugs Market
17.1. Eastern Europe Gastric Cancer Drugs Market Overview
17.2. Eastern Europe Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Gastric Cancer Drugs Market
18.1. Russia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Gastric Cancer Drugs Market
19.1. North America Gastric Cancer Drugs Market Overview
19.2. North America Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Gastric Cancer Drugs Market
20.1. USA Gastric Cancer Drugs Market Overview
20.2. USA Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Gastric Cancer Drugs Market
21.1. South America Gastric Cancer Drugs Market Overview
21.2. South America Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Gastric Cancer Drugs Market
22.1. Brazil Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Gastric Cancer Drugs Market
23.1. Middle East Gastric Cancer Drugs Market Overview
23.2. Middle East Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Gastric Cancer Drugs Market
24.1. Africa Gastric Cancer Drugs Market Overview
24.2. Africa Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Gastric Cancer Drugs Market Competitive Landscape And Company Profiles
25.1. Gastric Cancer Drugs Market Competitive Landscape
25.2. Gastric Cancer Drugs Market Company Profiles
25.2.1. Eli Lilly and company
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Novartis
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Merck KGaA
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Otsuka Pharmaceutical
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. F. Hoffmann-La Roche
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Gastric Cancer Drugs Market

27. Gastric Cancer Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Gastric Cancer Drugs Market Future Outlook and Potential Analysis

30. Appendix

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott
  • AstraZeneca
  • Boston Biomedical
  • Danaher corporation
  • GlaxoSmithKline PLC
  • Merck KGaA
  • MORE
The gastric cancer drugs market consists of sales of drugs for gastric cancer. Gastric cancer, also known as stomach cancer, is the formation of abnormal cells on the lining of stomach resulting in stomach pain and indigestion.

The global gastric cancer drugs market was valued at about $1.4 billion in 2018 and is expected to grow to $2.13 billion at a CAGR of 11.1% through 2022.

Asia Pacific was the largest region in the gastric cancer drugs market in 2018 and is forecasted to register the highest CAGR during 2018-2023.

Increasing number of obesity cases and smoking population increased number of people suffering from gastric cancer. Consuming tobacco and following diet unhealthy diet increases the risk of stomach cancer. According to American Institute For Cancer Research ,1 million new cases of stomach cancer have been reported in 2018. Similarly, according to the estimates of American Cancer Society in 2019, about 27,510 cases of stomach cancer will be diagnosed and 11,140 people will die from stomach cancer. Increase in number of cases in gastric cancer will drive the market for gastric cancer drugs.

Stringent regulations and policies for approval of the drugs restrain the market for gastric cancer drugs. Different regions have their own set of rules, guidelines and regulations set by their respective drugs regulation board. For example, the USFDA regulations for American pharmaceuticals states various conditions with regards to safety and effectiveness of the drug as well as certain labeling requirements. Similarly, the European medicines agency (EMA) gives licenses to the approved drugs before they can be marketed or commercialized in the European continent. Teysuno, a drug for advanced gastric cancer can be only obtained through a valid prescription and the protocol is that every company must assess the effects of using Teysuno and must list out the precautions to be taken by patients and healthcare providers to minimize any possible side effects. These regulations hinder the growth of the gastric cancer drugs market.

Many companies are using combination therapies to cure gastric cancer. Combination therapies help in treating patients with two or more drugs for a single disease and help in better treating the patients. For instance, in 2019, the USFDA has approved Taiho Oncology Inc’s combined product LONSURF trifluridine/tipiracil for pretreated metastatic gastric cancer. This approval is significant for patients living with advanced gastric or GEJ (gastroesophageal junction) adenocarcinoma who have limited effective treatment options after failure of standard treatment options. Advances in the drugs for treatment of gastric cancer will have a positive influence on the gastric cancer drugs’ market.

The gastric cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others. For instance, FDA's Current Good Manufacturing Practice (CGMP) regulation lays down minimum requirements for the methods and facilities used in manufacturing, processing, and packing of a drug product and ensures the quality of drugs produced by manufacturers. Moreover, FDA's guidance provides recommendations to applicants for cancer clinical trials and shows support in new drug applications (NDAs), biologics license applications (BLAs), or supplemental applications.

On April 2019, AstraZeneca, a multinational pharmaceutical and biopharmaceutical company acquired Daiichi Sankyo for $1.35 billion. This acquisition will help AstraZeneca to jointly develop drug Trastuzumab Deruxtecan with Daiichi Sankyo. This drug would help to treat people suffering from breast and gastric cancer. Daiichi Sankyo headquarted at Japan is a global pharmaceutical company which offers innovative products and a robust pipeline for cancer treatment.

Major players in the market are Eli Lilly and company, Novartis, Merck KGaA, Otsuka Pharmaceutical, F. Hoffmann-La Roche
Note: Product cover images may vary from those shown
5 of 5
  • Eli Lilly and company
  • Novartis
  • Merck KGaA
  • Otsuka Pharmaceutical
  • F. Hoffmann-La Roche
  • GlaxoSmithKline PLC
  • Bristol-Myers Squibb
  • Sanofi
  • Pfizer
  • AstraZeneca
  • Bayer Healthcare
  • Abbott
  • AROG Pharmaceuticals
  • Ipsen Biopharmaceuticals
  • Array Biopharma
  • Taiho Oncology
  • AstraZeneca
  • ARIAD Pharmaceuticals
  • Ono Pharmaceutical
  • Jiangsu HengRui Medicine
  • Gilead Sciences
  • Celgene/Taiho
  • Boston Biomedical
  • Imugene Limited
  • Boehringer Ingelheim
  • Daiichi-Sankyo
  • Danaher corporation
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll